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Introduction: Preeclampsia (PE) is a major cause of fetal morbidity and mortality. In the West-
ern  World, PE affects 2–7% of pregnancies and is responsible for 50,000 deaths annually. Early
detection is a priority as it can change the clinical course, but there are no biomarkers or
instrumental methods with high sensitivity and speciﬁcity. Only the hyperbaric index has
a  sensitivity and speciﬁcity of 99% for early identiﬁcation of pregnant women at risk of
developing PE, but its use is not widespread.
Objective: To assess the usefulness of the hyperbaric index in the primary prevention of
hypertensive pregnancy complications in a public healthcare area.
Material and methods: This is a retrospective study of pregnancies that occurred in our area
during the period 2007–2012 (N = 11,784). The diagnosis was established by the hyperbaric
index and pregnant women at risk were treated with ASA at night.
Results: In pregnant patients referred to the nephrology clinic (38.2%), diagnosed as high-
risk for PE, and treated with 100 mg ASA/night (from week 17), the incidence of PE episodes
was reduced by 96.94%.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Índice  hiperbárico  en  la  prevención  primaria  de  las  complicaciones
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Hipertensión
Introducción La preeclampsia (PE) es una importante causa de morbimortalidad fetal, que
en  el mundo occidental afecta al 2–7% de los embarazos y es responsable de 50.000 muertes
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anuales. La detección precoz es prioritaria, ya que puede cambiar su curso clínico, pero no se
dispone de biomarcadores ni métodos instrumentales de alta sensibilidad y especiﬁcidad,
solamente el índice hiperbárico tiene una sensibilidad y una especiﬁcidad del 99% para la
identiﬁcación precoz de las gestantes en riesgo de desarrollo de PE, pero está escasamente
difundido.
Objetivo: Valorar la utilidad del índice hiperbárico en la prevención primaria de las compli-
caciones hipertensivas del embarazo en un área sanitaria.
Material y métodos: Estudio retrospectivo realizado entre los embarazos habidos en nuestra
área  durante el periodo 2007–2012 (N = 11.784). El diagnóstico se estableció mediante el índice
hiperbárico y las gestantes en riesgo fueron tratadas con AAS nocturno.
Resultados: En las gestantes remitidas a consulta de Nefrología (38,2%), diagnosticadas de
alto  riesgo de PE y tratadas con AAS 100 mg nocturno (desde la semana 17) se redujo la
incidencia de episodios de PE un 96,94%.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
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from Obstetrics to HR clinics in regional centers was excep-ntroduction
igh blood pressure (HTN) is the most common clinical
omplication during pregnancy, and preeclampsia (PE) is a
ajor cause of fetal morbi-mortality (low-birth weight or pre-
ature birth), and maternal complications including acute
enal failure, HELLP syndrome, liver failure and even brain
dema, seizures and death.1 In the Western world, PE affects
 2–7% of all pregnancies, and the basic pathogenic phe-
omenon is endothelial dysfunction caused by an imbalance
f angiogenic factors producing placental abnormalities with
schemia. Endothelial dysfunction is not a limited process that
s resolved at birth, but may persist and pose a future cardio-
ascular risk.2
Therefore, even though PE should be diagnosed early,
ngiogenic factors are not sensitive or speciﬁc enough to be
sed in clinical practice3,4; neither is hyperuricemia, although
t is often correlated with the degree of severity early initiation
f PE; according to two recent systematic reviews, evidence
upporting a correlation between hyperuricemia and PE is
imited.5 In addition, these reviews have shown that uric acid
s a poor predictor of maternal-fetal complications.6 In our
xperience, based on the use of the hyperbaric index (HBI) as
he gold standard, risk factors including primiparous pregnan-
ies in advance age, use of oral contraceptive drugs, or a family
istory of HTN are predictive of PE.7
For instrumental methods, experts do not recommend
he use of the uterine artery Doppler8; however, the HBI or
he area of blood pressure (BP) excess above the upper limit
f the tolerance range has a 99% sensitivity and speciﬁcity
or the early screening of pregnant patients at risk of PE9;
nly the identiﬁcation serpina1 by the proteomic proﬁling of
rine10 or the evidence of podocyturia have a 100% sensitivity
nd speciﬁcity.11 Once the risk is detected, PE is signiﬁcantly
educed by the early administration of ASA12 and vitamin D13
t night.
Therefore, the diagnosis is made with an HBI greater than
2, in addition to conventional risk factors, and prevention
ncludes a high-dose of ASA, 100–300 mg  at night, resulting
n a signiﬁcantly reduced risk of hypertensive complications
esulting from pregnancy before week 17.(http://creativecommons.org/licenses/by-nc-nd/4.0/).
The objective of the present work is to assess the use of the
HBI for the primary prevention of PE in our health sector.
Materials  and  methods
This was a retrospective study in pregnant women followed in
our area between 2007 and 2012 (N = 11,784). We reviewed the
incidence of PE in pregnant women with high risk (HR) con-
sultations and consultations “without HR” from three local
hospitals (University Hospital Complex of Ourense [Complejo
Hospitalario Universitario de Ourense, CHUOU]), the regional hos-
pital ([Hospital Comarcal, HC] of Verín and Valdeorras) and in
HR pregnant women referred to Nephrology Consultation (NC)
services. In pregnant women referred to NC (before the 17th
week of pregnancy), BP was monitored for 48 hs as an outpa-
tients using Spacelab 92007. An HBI of greater than 12 was
considered a marker of PE risk (Fig. 1), and pregnant women
with a pathologic HBI were treated with 100 mg  of AAS and
vitamin D supplements at night provided that they had vita-
min  D deﬁciency. These pregnant women were monitored
throughout pregnancy in the nephrology outpatient clinics.
HR pregnant women were deﬁned as women who  met  any
of the following criteria: elderly pregnant woman, morbid obe-
sity, previous history of PE, diabetes mellitus, HTN, systemic
disease (DLE, antiphospholipid syndrome), cardiopathy, fam-
ily history of cardiovascular disease, smoking, twin pregnancy,
or use of oral contraceptives.
Results
The total number of deliveries between 2005 and 2012 was
11,784 (Fig. 2), of which 85.20% took place in the CHUOU, 7.82%
in the HC of Valdeorras, and 6.91% in the HC of Verín, and the
mean age of these pregnant women attended in these differ-
ent centers ranged from 30 to 31.63 years old (Fig. 2). Referraltional: 0.4% in the HC of Valdeorras and 1.70% in the HC of
Verín, whereas in the CHUOU, the percent of referrals was of
14.28%. Only 34.93% of these pregnant women were referred
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Fig. 1 – (A) Normal ABPM. Excess area (red circle) less than 12. (B) Pathological ABPM. Excess area (red circle) greater than 12;
the arrow points to the “excess area”: HBI is above a normal blood pressure threshold for pregnant woman.
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N.º total Partos 2005-2012
n: 11,874
HC Valdeorras
n: 922
Edad: 30,25 (16-41)
No AR
n: 918
Edad: 30,85
(16-46)
n: 4
Edad: 32
(21-42)
n: 1.434
Edad: 33,37
(14-48)
CN
n: 890 + 8.606
9.490
PE: 13PE: 98PE: 4HELLP: 1
20 episodios/año oña/soidosipe3,2oña/soidosipe8,0
n: 544
Edad: 35,3
(20-47)
IHB > 12: 61,8%
IHB < 12: 38,2%
n: 8.066
Edad: 31
(14-47)
n: 14
Edad: 31
(22-38)
n: 808
Edad: 30
(16-45)
No AR No ARAR RARA
n: 10.040
Edad: 31,63 (14-48)
n: 822
Edad: 30 (16-45)
CH ourense HC Verin
PE: 20
4 episodios/año
Fig. 2 – Total number of deliveries between 2005 and 2012.
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fo NC, 61.8% of them had a HBI greater than 12, while 32.8% of
hem showed a normal HBI.
The incidence of PE was 4 episodes/year in the HC of
aldeorras and 2.3 episodes/year in the HC of Verín. In
he CHUOU, the incidence of PE among pregnant women
ho  were not referred to NC was 20 episodes/year, whereas
.8 episodes/year were reported among patients attending
Cs including four pregnant women, two of whom had DLE,
he third had intolerance to ASA, and the fourth had HELLP
yndrome.
iscussion
E is a syndrome characterized by HTN and proteinuria after
he 20th week of pregnancy in women with no previous history
f HTN or proteinuria. In the Western world it affects between
% and 7% of all pregnancies, although it may threefold greater
n other geographical regions.14 Mortality is 10–15%, with
early 50,000 deaths every year. Therefore, early detection is
rucial and may alter its clinical course.
The basic mechanism is a defect in placental implanta-
ion. In a normal pregnancy the cytotrophoblast overregulates
etalloproteinase expression causing the conversion of
pithelium to endothelium, a process mediated by the vas-
ular endothelium growth factor (VEGF), the placental growth
actor (PIGF), and angiopoietin.In PE, there is an increase in placental and serum levels
of the antiangiogenic circulating factor, sFlt-1, which binds to
PIGF and VEGF and inhibits the interaction with its endothelial
receptors (FIt1); as a result, NOSe is also activated, resulting
in oxidative stress and placental ischemia. In PE, these fac-
tors are elevated levels at weeks 9 and 11, together with a
concurrent decrease in PGF before the onset of PE.15
In addition to angiopoietin,16 other factors involved in
the development of PE are low oxygen rates, resistance to
insulin,17 and vitamin D deﬁciency. VEGF is regulated by
vitamin D,18 and vitamin D deﬁciency-insufﬁciency in PE
women leads to endothelial dysfunction and HTN. Finally,
among other problems, placental abnormalities in the mother
give rise to increased peripheral resistances due to the activity
of AT1 agonistic antibodies19 and increased endoglin levels,
a co-receptor of TGF B1 and TGF B3, which acts as a potent
anti-angiogenic protein, “kidnapping” PGF and VEGF.
Paradoxically, none of these factors have the sensitivity-
speciﬁcity and availability required for clinical use3 in the
early diagnosis of PE, neither are conventional vascular risk
factors5,6 or instrumental methods,8 except for BP. In early
pregnancy, BP was classically considered to be useful for PE
screening, and although accuracy was higher when mean BP
was above 90 mmHg, its predictive value was low.20 These poor
outcomes of the static measurement of BP resulted from the
use of the threshold for the deﬁnition of essential HTN. The
pattern of BP in women with PE or HTN is known to be dif-
ferent and predictable; this way, differences in BP between a
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normotensive pregnant woman and a pregnant woman with
complications (PE or gestational HTN) are detected from the
ﬁrst trimester with signiﬁcant differences in the circadian
MESOR of systolic (12 mmHg) and diastolic (7 mmHg) BP. As
a result, the “quantiﬁcation” of the “excess” in the threshold
of BP or HBI, with a 99% sensitivity-speciﬁcity, allows for the
screening of pregnant women at risk of PE.9
In our series, HBI was pathological in 61.9% of pregnant
women referred from HR visits, but it was normal in 38.2%,
thereby showing that HBI allows for a more  accurate differenti-
ation than conventional AR criteria.9 Pregnant women at high
risk of PE were identiﬁed “early”, and treatment decreased
its incidence from 26.3 to 0.8 episodes/year, mainly in the
CHUOU, which accounts for the 34% of HR pregnant women
we received. No HR pregnant women came from the 2 HC, and
the rate of PE remained similar to that of areas where pri-
mary  care is not available.14 Protocols are common and this
situation may have resulted from “clinical inertia”.
Activated platelets and coagulation system, leading to an
imbalance between the synthesis of prostacyclins and throm-
boxane A2, result from the ischemic placental damage in
PE. Therefore, several studies to assess the use of antiaggre-
gants in the primary prevention of PE were conducted, but
the initial results were discouraging,21–23 although a review
report24 reveals how the risk of PE is reduced by 17% by the
use of antiplatelets. All these studies have a methodologic
problem: the dose of ASA and the dosing schedule. Several
studies have shown that 100–150 mg/dl of ASA is effective
compared to lower dosing (50–80 mg/dl)25 and that it should
be administered before week 17 and at night,12 considering
that inhibition of the thromboxane A2 synthesis by ASA is
dose-dependent and that the dose is administered at night.
Consequently, all pregnant women referred to NC (34.92%) and
with a HBI greater than 12 (61.8%) (Fig. 2) were treated with
100 mg  of ASA at night during the entire pregnancy, and the
incidence of PE episodes was decreased 96.94%.
In conclusion, the use of NC for the primary prevention of
HTN complications during pregnancy and the use of the HBI as
a diagnostic method is highly effective, and this is why routine
healthcare exams should be conducted between HR consulta-
tions and Nephrology consultations during pregnancy.
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